^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors

Published date:
07/05/2022
Excerpt:
IMGC936 exhibited cytotoxicity toward ADAM9-positive human tumor cell lines, as well as bystander killing, potent antitumor activity in human cell line-derived xenograft and patient-derived xenograft tumor models...
DOI:
10.1158/1535-7163.MCT-21-0915